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Objective: Atrial fibrillation is a rhythm disorder commonly seen early after coro-
nary artery bypass grafting, and it increases morbidity.
Methods: To investigate the effectiveness of magnesium sulfate in the prophylaxis
of atrial fibrillation, we conducted a prospective, randomized, placebo-controlled
clinical study on 200 consecutive patients in whom we performed elective and initial
coronary artery bypass grafting operations. In each group 50% of patients underwent
beating-heart operations. In the treatment group 100 patients (76 men and 24
women; mean age, 57.63  9.68 years) received 24.34 mEq (3 g) of magnesium
sulfate in 100 mL of saline solution that was administered over 2 hours (50 mL/h)
preoperatively, perioperatively, and at postoperative days 0, 1, 2, and 3. In the
control group 100 patients (74 men and 26 women; mean age, 59.96  9.29 years)
received only 100 mL of saline solution according to the same administration
schedule as the treatment group.
Results: Atrial fibrillation developed in 15 patients from the treatment group and in
16 patients from the control group. The arrhythmia developed after 37.87  12.76
and 45.26 15.27 hours in the treatment and control groups, respectively. Although
a significant relationship was found between low magnesium sulfate levels and
increased incidence of atrial fibrillation (P  .05), when the incidence of postop-
erative atrial fibrillation is concerned, no significant difference was found between
the 2 groups (P  .05). Also, no significant difference was found between opera-
tions with cardiopulmonary bypass and beating-heart operations in terms of atrial
fibrillation incidence (P  .05). However, atrial fibrillation extended the duration of
hospital stay in both groups (P  .05).
Conclusion: Our findings indicate that magnesium sulfate infusion alone is not
sufficient for the prophylaxis of atrial fibrillation.
Atrial fibrillation is among the common complications seen earlyafter coronary artery bypass grafting (CABG). Its mechanism ofdevelopment has not been clearly defined, and its frequencyincreases with older age. The frequency of atrial fibrillation hasnot decreased despite recent developments in cardiac surgicaltechniques, anesthetic management, and myocardial protection. It
generally occurs between 24 and 96 hours postoperatively, being seen most com-
monly on the second postoperative day. Atrial fibrillation potentially leads to
complications, including early and midterm thromboembolic events, hemodynamic
disorders, extended duration of hospitalization, and increased costs. It is not only a
rhythm disturbance, but also quite a serious morbidity factor because of its com-
plications, and therefore prophylaxis is very important.1
Until now, many pharmacologic agents have been used to prevent atrial fibril-
lation. In most but not all studies, -blockers2 and amiodarone1 have been shown to
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decrease the development of postoperative atrial fibrillation.
In only 33-5 of the randomized controlled clinical magne-
sium sulfate trials1-10 relevant to this issue, magnesium
sulfate was suggested to decrease the postoperative devel-
opment of atrial fibrillation.
In this study we aimed to investigate the effectiveness of
magnesium sulfate in the prophylaxis of atrial fibrillation
and discuss the subject in light of published data.
Patients and Methods
To investigate the effect of magnesium sulfate on the development
of postoperative atrial fibrillation, we conducted a prospective,
randomized, placebo-controlled trial in 200 consecutive patients
who underwent elective and initial CABG operations in our center.
The study was approved by the hospital ethics committee, and
informed consent was obtained from all patients. Operations and
management of atrial fibrillations were performed by the same
surgical team.
In the treatment group (n  100) 24% of the patients were
women, and 76% were men; the average age was 57.63  9.68
years (range, 41-76 years). The control group also consisted of 100
patients (74 men and 26 women; mean age, 59.56  9.29 years;
age range, 44-80 years). All patients underwent elective CABG.
They all had sinus rhythm preoperatively. Fifty percent of opera-
tions in both the treatment and control groups were beating-heart
operations.
EuroSCORE (European System for Cardiac Operative Risk
Evaluation) was used for preoperative risk scoring. According to
EuroSCORE, preoperative mean predicted risk score was 1.75%
for the treatment group (0.08% for 54 patients, 3% for 42 patients,
and 11.2% for 4 patients), whereas it was 2.15% for the control
group (0.08% for 60 patients, 3% for 29 patients, and 11.2% for 11
patients).
There was no difference between the 2 groups in terms of
preoperative use of -blocker (P .717), calcium-channel blocker
(P  .661), angiotensin-converting enzyme inhibitor (P  .650),
or digoxin (P  .470, binary logistic regression analysis). The 2
groups did not differ in terms of other preoperative characteristics.
Data related to cases are summarized in Table 1. For determination
of the effect of magnesium sulfate on atrial fibrillation incidence
and to provide homogeneity for additional medication use, preop-
erative -blockers were continued until 1 day before the operation,
they were discontinued by the initiation of magnesium sulfate
administration, and -blocker administration was not used unless
it was necessary. No statistically significant difference was found
in either group (treatment and control) between patients who used
-blockers preoperatively and those who did not use them in terms
of atrial fibrillation development.
Magnesium sulfate was administered each time as an infusion
of 24.34 mEq ( 3 g  2 ampules [1 ampule  12.17 mEq  1.5
g]) in 100 mL of saline solution for a duration of 2 hours and with
a rate of 50 mL/h. This dose was administered 12 hours before the
operation to all patients, after termination of cardiopulmonary
bypass in patients who were operated on with cardiopulmonary
bypass, and after anastomosis of the last graft in patients who
underwent beating-heart operations (perioperative dose), and it
was repeated in all cases at postoperative days 0 (first dose ad-
ministered postoperatively in the intensive care unit), 1, 2, and 3.
The timing and dosage of magnesium sulfate administration
were as follows. Because preoperative magnesium sulfate levels
were close to the lower limit of normal in both groups, magnesium
sulfate was administered preoperatively to all patients. Magnesium
sulfate was administered perioperatively to patients who undergo
cardiopulmonary bypass because hypomagnesemia is generally
observed in these patients, and it was also administered periopera-
tively to patients who underwent beating-heart operations to pro-
vide a standard. Because magnesium sulfate decreases to its min-
imal level usually at the first postoperative day and it usually does
not return to normal levels before the fourth postoperative day,
magnesium sulfate was also given at days of 0, 1, 2, and 3. Dosage
was determined in the view of the current literature and clinical
experience.
We preferred the intravenous route instead of the oral route to
attain a rapid and effective result. Because we had to administer
the drug in the operating room through the intravenous route, we
preferred the intravenous route during both the preoperative and
postoperative periods to provide a standard for administering mag-
nesium sulfate.
Only 100 mL of saline solution was administered to the control
group for the placebo effect. In addition to magnesium sulfate
replacement, patients were also given potassium so as to keep
TABLE 1. Preoperative characteristics of patients and anal-
ysis of influence of these parameters on atrial fibrillation
development
Variables
Treatment
group
(n  100)
Control
group
(n  100) P value
Age* 57.63 9.68 59.56 9.29 —
Patients 60 years,
of age (%)
47 54
Patients 60 years,
of age among pa-
tients with AF (%)
62.5 77.7 .174
Sex
Male 76 74 —
Female 24 26 .183
Previous myocardial
infarction (%)
62 58 .637
Hypertension (%) 45 54 .608
Diabetes mellitus (%) 17 23 .550
Hypercholesterolemia
(%)
36 38 .155
LVEF (%)
50 36 41 —
30-50 40 38 —
30 24 21 —
50 .620
Mean magnesium
sulfate level*
1.95 0.38 1.96 0.42
Effect of low MgSO4
level (1.8 mg/dL) on
development of AF
.003
AF, Atrial fibrillation; LVEF, left ventricular ejection fraction.
*Mean  SD.
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potassium levels at greater than 4 mmol/L. Intraoperative and
postoperative characteristics of both groups are summarized in
Table 2; supraventricular arrhythmias developed perioperatively
and postoperatively (in the intensive care unit or wards), as shown
in Table 3. Table 4 shows the timing of atrial fibrillation devel-
opment and durations of intensive care unit and hospital stay.
Graphic analysis of preoperative, perioperative, and postoper-
ative plasma magnesium sulfate levels of patients in the treatment
and control groups are shown in Figure 1. In the treatment and
control groups mean magnesium sulfate levels were as follows:
1. Treatment group: preoperative, 1.95  0.38 mg/dL; periop-
erative, 2.21  0.24 mg/dL; first postoperative day, 2.27 
0.19 mg/dL; second postoperative day, 2.39  0.19 mg/dL;
and third postoperative day, 2.49  0.14 mg/dL.
2. Control group: preoperative, 1.96  0.42 mg/dL; perioper-
ative, 1.85  0.33 mg/dL; first postoperative day, 1.76 
0.32 mg/dL; second postoperative day, 1.91  0.29 mg/dL;
and third postoperative day, 2.04  0.31 mg/dL.
Concurrent matrix presentation of the relationships between blood
potassium level, blood magnesium sulfate level, and heart rate in
31 patients (in 2 groups) who had atrial fibrillation is shown in
Figure 2.
Exclusion Criteria
Exclusion criteria included history of atrial fibrillation, history of
paroxysmal atrial fibrillation even though the patient is in sinus
rhythm just before the operation, preoperative heart rate of less
than 50 beats/min, concomitant valve surgery, redo coronary artery
surgery, blood pressure of less than 100 mm Hg, history of renal
failure (serum creatinine level  2.0 mg/dL), and severe respira-
tory function disorder.
Anesthetic Management
All patients received premedication with midazolam (Dormicum)
and scopolamine. Fentanyl, propofol (Diprivan), and pancuronium
bromide (Pavulon) were administered for induction of anesthesia.
Sevoflurane (Sevorane) 1 to 1.5 vol% was used as an inhalational
anesthetic agent.
Operative Procedures
In patients in whom cardiopulmonary bypass was performed,
aortic and right atrial 2-staged cannulation, systemic hypothermia
(32°C), and antegrade repeated blood cardioplegia were used. In
CABG operations on beating hearts, Octopus II and III cardiac
stabilizers (Medtronic Inc, Minneapolis, Minn) were used. In all
patients who were operated on with cardiopulmonary bypass, a
membrane oxygenator (S.p.A. Mirandola, Italy) and centrifugal
pump (Sarns Delphin II, Sarns, Inc, Ann Arbor, Mich) were used.
During cardiopulmonary bypass, blood flow rate and systemic
perfusion pressure were kept at greater than 2.5 Lm2min1
and 50 mm Hg, respectively. The left internal thoracic artery was
used for the left anterior descending artery, and a saphenous vein
graft was preferred for other coronary arteries. The intraoperative
use rate of the left internal thoracic artery was similar between the
2 groups.
Postoperative Data
After completion of the surgical procedure, patients were taken to
the intensive care unit. Treatment group patients were extubated
after an average of 4.18  1.15 hours, and control group patients
were extubated after an average of 4.0 1.31 hours. There was no
statistically significant difference between groups in terms of tim-
ing of extubation (P  .317, independent-samples t test). Patients
were taken to the wards when their hemodynamic and respiratory
functions were stable.
TABLE 3. Supraventricular arrhythmias developing periop-
eratively or postoperatively in intensive care unit and
wards
Variables
Treatment
group
(n  100)
Control
group
(n  100) P value
Atrial extrasystoles (%) 3 5 .360
Episodes of supraventricular
tachycardia (%)
2 4 .341
Atrial fibrillation (%) 15 16 .845
TABLE 2. Intraoperative and postoperative characteristics
of patients
Variables
Treatment
group
(n  100)
Control
group
(n  100) P value
With CPB (%) 50 50
On beating heart (%) 50 50
No. of grafts* 1.33 0.68 1.69 0.63
Duration of CPB (min)* 78.46 29.14 77.66 29.23 .891
In patients with AF* 85.14 19.74 85.67 22.97 .751
Duration of aortic CC (min)* 37.76 15.48 38.04 15.43 .928
In patients with AF* 44.00 11.45 43.33 13.24 .958
Blood transfusion (U)
With CPB* 2.86 1.48 3.02 1.61 .607
On beating heart* 1.90 1.29 2.02 1.33 .649
AF, Atrial fibrillation; CC, aortic crossclamping; CPB, cardiopulmonary
bypass.
*Mean  SD.
TABLE 4. Timing of atrial fibrillation development and du-
rations of intensive care unit and hospital stays
Variables
Treatment
group
(n  100)
Control
group
(n  100) P value
Onset of AF (h)* 37.87 12.76 45.26 15.27 .140
(15 patients) (16 patients)
Length of ICU stay (h)* 22.40 4.79 23 4.46 .650
Length of hospital stay (d)* 5.16 1.18 5.67 1.31 .004
In patients with AF (d) 6.0 1.2 6.31 0.87 .410
AF, Atrial fibrillation; ICU, intensive care unit.
*Mean  SD.
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Onset of atrial fibrillation was considered as sufficient criteria
for the initiation of treatment. In our clinical practice we used
amiodarone or -blocker for patients with atrial fibrillation. In all
but 2 patients, sinus rhythm was restored within 24 hours. Exam-
inations done on the fifth postoperative day revealed that these 2
patients also returned to sinus rhythm.
Follow-up Monitoring
Rhythm was monitored continuously during the operation and
during the first 2 postoperative days (Datascope 2001A, Datascope
Corp, Montvale, NJ). In the wards patients were monitored with a
12-lead electrocardiography and telemetry system (Cardiac Telem-
etry System, DynaScope, Fukuda Denshi Co, Ltd, Tokyo, Japan) if
physical examination revealed a tachycardia attack or the devel-
opment of an arrhythmia or if a patient had palpitation or any
rhythm-related complaint.
Arrhythmia Status
Arrhythmias that developed perioperatively or postoperatively in
intensive care units or wards were classified as atrial extrasystole
(3% and 5% for the treatment and control groups, respectively;
P  .360, 2-sided Fisher exact test), supraventricular tachycardia
attacks (2% and 4% for the treatment and control groups, respec-
tively; P  .341, 2-sided Fisher exact test), and atrial fibrillation
(15% and 16% for the treatment and control groups, respectively;
P  .845, 2-sided Pearson 2 test; Table 3).
Laboratory Analysis
Blood magnesium sulfate levels were measured 12 hours and 1
hour before the operation, during the operation, 1 hour after the
operation, and at the first, second, and third postoperative days
(Table 2). Normal limits of magnesium sulfate level were consid-
ered to be 1.8 to 2.5 mg/dL. Potassium replacement was done to
keep potassium levels between 4.0 and 5.0 mmol/L to prevent
electrolyte imbalance.
Statistical Analysis
Statistical procedures were done by using SPSS 10.0 (SPSS Inc,
Chicago, Ill) and MATLAB 6.0.88 Release 12 (The MathWorks,
Inc, Boston, Mass) software. Data are expressed as means  SD.
The Pearson 2 test, the Fisher exact test, log linear analysis, the
Levene f test, the independent-samples t test, the Mann-Whitney U
test, binary logistic regression analysis, and multivariate linear
regression analysis were used for statistical evaluation of the data.
Contribution of operation technique to the development of
atrial fibrillation was evaluated with the Pearson 2 test. For
comparing the treatment and control groups in terms of the fre-
quency of atrial fibrillation the Pearson 2 test was used. For
evaluating the effect of atrial fibrillation development on the
duration of hospitalization in each group, comparison of 2 inde-
pendent group means was aimed. The Levene f test was used for
testing the homogeneity of variances, and variances were found to
be homogeneous. Although group variances were homogeneous,
the nonparametric counterpart of t test (Mann-Whitney U test) was
used because the number of subjects to be compared (patients who
did and did not have atrial fibrillation) was not equal. For com-
parison of mean durations of hospitalization between groups, the
independent-samples t test was used (t test for equality of means,
P  .004; 95% confidence interval of the difference [CID] lower
limit of 0.8576 and CID upper limit of 0.1624). For compar-
ison of patients who had atrial fibrillation in terms of duration of
hospitalization, the independent-samples t test was used (t test for
equality of means, P .410; 95% CID lower limit of1.0778 and
CID upper limit of 0.4528). For comparison of independent group
Figure 1. Graphic analysis of preoperative (Preop), perioperative (Periop), and postoperative plasma magnesium
sulfate concentrations for each group.
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ratios for atrial extrasystole and supraventricular tachycardia seen
in the treatment and control groups, the Fisher exact test was used,
and the Pearson 2 test was used for atrial fibrillation.
The Levene f test for equality of variance was done to compare
intubation durations in 2 groups. Because the variances were
homogeneous, the independent-samples t test was used (P  .317,
95% CID lower limit of 0.1710 and CID upper limit of 0.5244).
Effects of cardiopulmonary bypass and aortic crossclamping du-
rations on atrial fibrillation were assessed by using the nonpara-
metric Mann-Whitney U test. Because of the dichotomy (nominal)
characteristic of atrial fibrillation (dependent variable), the impor-
tance of risk factors for the development of atrial fibrillation was
determined with binary logistic regression analysis. Independent
variables were age, sex, hypertension, previous myocardial infarc-
tion, hypercholesterolemia, left ventricular ejection fraction, blood
transfusion, and serum magnesium sulfate level. The relationship
between atrial fibrillation and other characteristics of patients who
had atrial fibrillation and had low and normal-high magnesium
levels were investigated by using the log linear analysis test. No
statistically significant difference was found in terms of the devel-
opment rate of atrial fibrillation (P  .05). For assessment of the
correlation between heart rate and serum magnesium sulfate level
in both groups, the dependent variable was heart rate (by days),
and the independent variable was serum magnesium sulfate level
(by days). The multivariate linear regression analysis was used,
and no statistically significant correlation was found (P  .158).
Results
The primary end point of the study was postoperative de-
velopment of atrial fibrillation, and secondary end points
were ventricular rate at the onset of atrial fibrillation, day of
onset of atrial fibrillation, and duration of hospitalization.
Sex, hypertension, diabetes mellitus, hypercholesterolemia,
previous myocardial infarction, disorder of left ventricular
function, number of grafts, duration of aortic crossclamp-
ing, duration of cardiopulmonary bypass, magnesium sul-
fate level, preoperative transfusions, and postoperative
transfusions did not affect the development of atrial fibril-
lation. The incidence of atrial fibrillation was increased 1.37
times by female sex (P  .183), 1.12 times by hypertension
(P  .608), 1.11 times by previous myocardial infarction
(P .637), 1.12 times by left ventricular functional disorder
(ejection fraction 50%, P  .620), 1.39 times by hyper-
cholesterolemia (P .155), and 1.03 times by perioperative
or postoperative transfusion (treatment group: 2.38  1.47
Figure 2. Concurrent matrix presentation of the relationships between blood potassium level, blood magnesium
sulfate level, and heart rate in 31 patients (in 2 groups) in whom atrial fibrillation developed.
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U, control group: 2.52  1.55 U; P  .831, binary logistic
regression analysis). Risk factors, including diabetes melli-
tus (P  .550, binary logistic regression analysis), number
of grafts, duration of aortic crossclamping (P  .07), and
duration of cardiopulmonary bypass (P  .134, 2-tailed
Mann-Whitney U test) did not influence the development of
atrial fibrillation. The mean magnesium sulfate level of
patients with atrial fibrillation on the day of atrial fibrillation
development was 2.31 0.44 mg/dL in the treatment group
and 1.74  0.39 mg/dL in the control group. Mean potas-
sium levels of patients with atrial fibrillation (total of 31
patients in the treatment and control groups) were 3.85 
0.23 mmol/L, and their mean magnesium sulfate levels were
2.01  0.50 mg/dL. In the treatment group 62.5% of pa-
tients with atrial fibrillation were older than 60 years, and in
the control group 77.7% of patients with atrial fibrillation
were older than 60 years. Although the incidence of atrial
fibrillation development over 60 years of age was high,
statistical analysis of these data revealed a P value of .174
(2-sided Pearson 2 test).
Magnesium sulfate administration did not cause severe
bradycardia or hypotension in any of the patients. Accord-
ing to the EuroSCORE risk scoring system, predicted mor-
tality rates were 1.75% and 2.15% in the treatment and
control groups, respectively. The observed mortality rate
was 1% in both groups (one patient in each group).
In the treatment group magnesium sulfate levels of pa-
tients with atrial fibrillation (15 patients) were low in 2
patients (both patients were operated on with cardiopulmo-
nary bypass), normal in 9 patients (4 with cardiopulmonary
bypass and 5 beating-heart operations), and high in 4 pa-
tients (1 with cardiopulmonary bypass and 3 beating-heart
operations). In the control group magnesium sulfate levels
of patients with atrial fibrillation (16 patients) were low in 9
patients (6 with cardiopulmonary bypass and 3 beating-
heart operations) and normal in 7 patients (3 with cardio-
pulmonary bypass and 4 beating-heart operations).
No statistically significant difference was found when
other characteristics of patients with atrial fibrillation, de-
spite a normal or high magnesium sulfate level, were com-
pared with the characteristics of patients with atrial fibril-
lation and had low magnesium sulfate levels (P  .05, log
linear analysis).
Preoperative, perioperative, and postoperative infusion
of magnesium sulfate did not cause a difference compared
with that seen in the control group in terms of atrial fibril-
lation development (P  .845, Pearson 2 test). Low serum
magnesium sulfate levels (1.8 mg/dL; normal values,
1.8-2.5 mg/dL) significantly increased (2.66 times) the risk
of atrial fibrillation development (P  .003, binary logistic
regression analysis). However, the relationship between
daily magnesium sulfate levels and heart rate was evaluated
by means of the multivariate linear regression method, and
no statistically significant correlation was found (P .158).
Atrial fibrillation developed after 37.87  12.76 and
45.26  15.27 hours in the treatment and control groups,
respectively. Distribution of patients who had atrial fibril-
lation according to the type of surgical procedure was as
follows: in the treatment group (n  15), 7 (14%) with
cardiopulmonary bypass and 8 (16%) beating-heart opera-
tions (P  .78) and in the control group (n  16), 9 (18%)
with cardiopulmonary bypass and 7 (14%) beating-heart
operations (P .58, Pearson 2 test). The incidence of atrial
fibrillation in patients undergoing beating-heart operations
was not statistically different from the atrial fibrillation
incidence of patients who were operated on with cardiopul-
monary bypass (treatment group: P  .779, control group:
P  .585, Pearson 2 test).
In the treatment group atrial fibrillation development
occurred at the second postoperative day in 80% of patients
(12 patients, 5 with cardiopulmonary bypass and 7 beating-
heart operations), at the first postoperative day in 13.3% of
patients (2 patients, 1 with cardiopulmonary bypass and 1
beating-heart operation), and perioperatively in 6.7% of
patients (1 patient with cardiopulmonary bypass; variable
with the highest frequency  2, 95% confidence interval 
1.4046-2.0621). In the control group, atrial fibrillation de-
velopment occurred at the second postoperative day in 75%
of patients (12 patients, 7 with cardiopulmonary bypass and
5 beating-heart operations), at the first postoperative day in
12.5% of patients (2 patients, 1 with cardiopulmonary by-
pass and 1 beating-heart operation), and at the third post-
operative day in 12.5% of patients (2 patients, 1 with
cardiopulmonary bypass and 1 beating-heart operation;
variable with the highest frequency  2, 95% confidence
interval  1.7248-2.2752). In the treatment and control
groups, respectively, 97% and 96% of patients were dis-
charged from the intensive care unit at the first postopera-
tive day. Thus atrial fibrillations occurred after discharge
from the intensive care unit, and therefore the effect of atrial
fibrillation development on the duration of intensive care
unit stay was not considered (P  .650, independent-sam-
ples t test). The mean duration of hospitalization was 5.16
1.18 days in the treatment group and 5.67 1.31 days in the
control group. The difference was statistically significant
(P  .004, independent-samples t test). The mean duration
of hospitalization for patients who had atrial fibrillation was
6.0  1.2 days in the treatment group and 6.31  0.87 days
in the control group. Development of atrial fibrillation ex-
tended the duration of hospital stay in both groups (treat-
ment group: P  .005, control group: P  .013, 2-tailed
Mann-Whitney U test). However, when patients with atrial
fibrillation in each group were compared, 2 groups did not
differ in terms of hospital stay (P  .410, independent-
samples t test).
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Discussion
The incidence of atrial fibrillation after CABG surgery is
10% to 40%. Although its causes are not clear, it is multi-
factorial; advanced age and low magnesium sulfate levels
are substantial risk factors.11,12
In atrial fibrillation with high ventricular response, car-
diac output decreases, and oxygen consumption of the heart
increases. This situation might lead to severe hemodynamic
problems, particularly in patient with left ventricular dys-
function. Cardiopulmonary bypass is not responsible alone
for the development of postoperative atrial fibrillation be-
cause atrial fibrillation might also be seen after CABG
operations performed on the beating heart, and its incidence
is not low in this group of patients. In addition to cardio-
pulmonary bypass, metabolic changes, body temperature,
right atrial temperature, cardioplegia content and its pattern
of administration, insufficient right atrial protection with
cardioplegia during aortic crossclamping, electrolyte imbal-
ances, anesthetic agents, durations of cardiopulmonary by-
pass and aortic crossclamping, suture technique for atrial
cannulation, stress, atrial enlargement, atrial infarction, lo-
cal surgical trauma, local pericardial inflammation, pericar-
dial dissection, age-related atrial atrophic changes, and dis-
continuation of preoperatively used -blockers might also
contribute to the development of atrial fibrillation.10,13 In
our study atrial fibrillation developed in 16% (n  8) and
14% (n  7) of patients (treatment and control groups,
respectively) undergoing beating-heart operations. How-
ever, no statistically significant difference was found be-
tween patients who were operated on with cardiopulmonary
bypass and those undergoing beating-heart operations in
terms of postoperative atrial fibrillation development.
Atrial fibrillation alone does not cause mortality; how-
ever, it might lead to hemodynamic disorders, thromboem-
boli and severe arrhythmia, perioperative morbidity (eg,
myocardial infarction and stroke), early and midterm mor-
tality, extended duration of intensive care unit stay and
hospitalization, and increased costs.8,14 No thromboembolic
complications developed in our series, despite development
of atrial fibrillation in 15% of the treatment group and 16%
of the control group. In the treatment group 97% of patients
and in the control group 96% of patients were discharged
from the intensive care unit at the first postoperative day.
Development of atrial fibrillations occurred after discharge
from the intensive care unit in the wards, and therefore
influence of atrial fibrillation development on the duration
of intensive care unit stay was not evaluated. In the treat-
ment group 80% of atrial fibrillations developed at the
second postoperative day, whereas in the control group 75%
of them occurred at the second postoperative day (at an
average of 37.87  12.76 and 45.26  15.27 hours in the
treatment and control groups, respectively).
The mean duration of hospitalization was 5.16  1.18
and 5.67  1.31 days in the treatment and control groups,
respectively. For patients who had atrial fibrillation, the
duration was 6.0  1.2 days in the treatment group and
6.31  0.87 days in the control group. As a result, atrial
fibrillation extended the duration of hospitalization in both
groups.
The effectiveness of -blockers and amiodarone in the
prophylaxis for atrial fibrillation has been proved.1,2 For
magnesium sulfate, however, it was suggested that it de-
creases3-5 or does not affect1,2,9,10 the incidence of atrial
fibrillation after CABG operations; some authors even sug-
gested that atrial fibrillation was provoked, and its incidence
was increased in patients with high magnesium sulfate
levels.8 We concluded, in our study, that magnesium sulfate
is not solely effective in the prophylaxis of atrial fibrillation.
A low magnesium sulfate level is arrhythmogenic be-
cause a decrease in magnesium sulfate level increases the
sensitivity of atrial myocardium, and arrhythmias such as
atrial fibrillation might develop. In patients who had atrial
fibrillation with a low magnesium sulfate level, this arrhyth-
mia is managed with magnesium sulfate infusion.15
Patients who undergo cardiopulmonary bypass have hy-
pomagnesemia. Postoperative hypomagnesemia is fre-
quently associated with atrial arrhythmias and extended
duration of intubation. Magnesium sulfate reaches its min-
imum level at the first postoperative day. Magnesium sul-
fate deficiency is due to hemodilution and intraoperative
and postoperative cellular depletion. Diuretic use, second-
ary hyperaldosteronism, high levels of epinephrine, in-
creased anabolic activity, extreme stress caused by sympa-
thetic activity, and increased urinary loss contribute to this
decrease. Magnesium sulfate reaches its preoperative values
at the fourth postoperative day.1,10 These findings indicate
the need for magnesium sulfate supplementation after and
during cardiac surgery.16,17
Some literature data suggest that preoperative high-dose
magnesium sulfate administration protects the cell during
ischemia and decreases the reperfusion injury. It was also
suggested that it also decreases the incidence of myocardial
infarction and supraventricular arrhythmia seen after car-
diac surgery. Magnesium sulfate decreases afterload, pro-
vides coronary vasodilatation, decreases platelet aggrega-
tion, and protects the cell against ischemia and reperfusion.2
Low magnesium sulfate levels are also associated with the
development of postoperative ventricular arrhythmias.2,18
Magnesium sulfate suppresses the cardiac arrhythmia
seen during acute myocardial infarction.19 Rasmussen and
colleagues20 found that magnesium sulfate prophylaxis pro-
vided a decrease from 47% to 21% in all arrhythmias.
Abraham and associates21 reported that administration of a
single dose of 2.4 g of magnesium sulfate during the early
phase of acute myocardial infarction decreased ventricular
arrhythmia incidence from 34.8% to 14.6%. Hypomag-
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nesemia is frequently seen during acute myocardial infarc-
tion. Magnesium sulfate decreases the mortality in 2 to 4
weeks after acute myocardial infarction.10
In our study the incidence of postoperative atrial fibril-
lation in the treatment group for hypomagnesemic patients
was 13.3% (2/15, 1.4  0 mg/dL). In addition, atrial fibril-
lation also developed in 9 (60%) patients with normal or 4
(26.7%) patients with high levels of magnesium sulfate. In
the control group 9 (56.25%) of 16 patients who had atrial
fibrillation had low magnesium sulfate levels (1.43  0.125
mg/dL), whereas 7 (43.75%) of them had normal levels.
When the incidence of atrial fibrillation was compared
between patients with low and normal magnesium sulfate
levels, it was found that atrial fibrillation incidence was
significantly increased in patients with low levels.
Maslow and colleagues22 reported that atrial fibrillation
could develop in CABG surgery done on beating hearts and
intraoperative administration of magnesium sulfate de-
creased the incidence of postoperative atrial tachyarrhyth-
mia; they recommended intraoperative supplementation of
magnesium sulfate. In our study the incidence of atrial
fibrillation in patients undergoing beating-heart operations
was not statistically different from that of patients operated
on with cardiopulmonary bypass.
A study by Jensen and colleagues23 that investigated
electrolyte changes in right atrial and skeletal muscles (pre-
operative, intraoperative, and postoperative) found that
magnesium sulfate did not decrease in skeletal muscle and
atrial muscle, but its serum level was decreased.
England and colleagues6 demonstrated that hypomag-
nesemic patients had higher supraventricular arrhythmia
incidence. We found that a low magnesium sulfate level
(significant when  1.8 mg/dL) increases the incidence of
atrial fibrillation 2.66 times. Parikka and associates8 found
that magnesium sulfate was not helpful in the prophylaxis of
atrial fibrillation, and they even demonstrated that atrial
fibrillation became more prevalent in patients with a high
magnesium sulfate level. Fanning,7 Karmy-Jones,9 and their
associates could not find a significant difference between
treatment and control groups in terms of incidence of atrial
fibrillation development. Fanning and coworkers7 only
found in their study that the total number of atrial fibrillation
episodes was decreased. We also could not find any differ-
ence between treatment and control groups with this respect.
Studies related to the effect of magnesium sulfate on the
incidence of supraventricular arrhythmia after CABG are
summarized in Table 5.1-10
In conclusion, atrial fibrillation, which develops early
TABLE 5. Studies investigating the effect of magnesium sulfate on the incidence of atrial fibrillation that develops after
coronary artery bypass grafting operations
Reference Study groups (n) Total Mg dosage (g) AF/AT (%) Effect of Mg on AF or AT
Fanning et al7 Mg, n 49 21 g, during 4 d Mg: 14.2% No significant difference; only total
number of AF episodes decreaseC, n 50 C: 28%
England et al6 Mg, n 50 2 g, over 30 min Mg: 34% No significant difference; if Mg is normal,
AT incidence decreasesC, n 50 C: 40%
Parikka et al8 Mg, n 69 17.5 g, during 48 h Mg: 29% No significant difference; if Mg increases,
AF incidence increases
C, n 71 C: 26%
Colquhoun et al5 Mg, n 66 12 g, during 48 h Mg: 16.7% Significant difference
C, n 64 C: 37.5%
Karmy-Jones et al9 Mg, n 46 14.4 g, over 24 h Mg: 26% No significant difference
C, n 54 C: 24%
Nurozler et al3 Mg, n 25 25 g, during 5 d Mg: 4% Significant difference
C, n 25 C: 20%
Solomon et al10 PMg, n 85 18 g, over 24 h P  Mg: 10% No significant difference
P, n 82 P: 18.5%
Treggiari-Venzi et al1 Mg, n 47 12 g, during 72 h Mg: 23% No significant difference
A, n 49 A: 14%
C, n 51 C: 27%
Bert et al2 Mg, n 63 12 g, during 96 h Mg: 38% No significant difference
C, n 60 C: 38%
D, n 62 D: 31%
DMg, n 62 D  Mg: 37%
P, n 71 P: 18%
PMg, n 69 P  Mg: 19%
Toraman et al4 Mg, n 100 7.3 g, during 5 d Mg: 2% Significant difference
C, n 100 C: 21%
Mg, magnesium; AF, atrial fibrillation; AT, atrial tachyarrhythmias; C, control; P, propranolol; A, Amiodarone; D, digoxin.
The cited studies were clinical randomized controlled trials.
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after CABG surgery, is a serious cause of morbidity and
extends the duration of hospitalization. Thus, prevention of
atrial fibrillation would not only provide physiologic and
hemodynamic benefits but will also cause cost savings.
Although low blood magnesium sulfate level increases the
incidence of atrial fibrillation, a significant benefit for pre-
vention of atrial fibrillation could not be attained with only
routine administration of magnesium sulfate. Intravenous
magnesium sulfate administration has a role in the treatment
of atrial arrhythmia; however, its administration alone is not
sufficient for the prophylaxis of atrial fibrillation.
We thank Abdurrahim Nur Sozudogru, MD, for his contribu-
tions to the preparation of the manuscript.
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